%D8%A8%D9%8A%D8%BA%D9%86%D8%AA%D9%8A%D8%B1%D9%81%D9%8A%D8%B1%D9%88%D9%86_%E2%80%93_%D8%A3%D9%84%D9%81%D8%A7_%E2%80%93_2%D8%A3Pegilirani_interferon_alfa-2aCategory:Interferon-alpha_2aPeginterferon_%CE%B1Peginterferon_alfa-2aPeginterf%C3%A9ron_alfa-2aPeginterferon_alfa-2a%E0%AC%AA%E0%AD%87%E0%AC%9C%E0%AC%BF%E0%AC%A3%E0%AD%8D%E0%AC%9F%E0%AC%B0%E0%AC%AB%E0%AD%87%E0%AC%B0%E0%AC%A8_%E0%AC%86%E0%AC%B2%E0%AC%AB%E0%AC%BE-%E0%AD%A8%E0%AC%8FPeginterferon_alfa-2a%D0%9F%D0%B5%D0%B3%D0%B8%D0%BB%D0%B8%D1%80%D0%BE%D0%B2%D0%B0%D0%BD%D0%BD%D1%8B%D0%B9_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD_%D0%B0%D0%BB%D1%8C%D1%84%D0%B0-2%D0%B0Pegilirani_interferon_alfa-2aPeginterferon_alfa-2aPegilirani_interferon_alfa-2a%D0%9F%D0%B5%D0%B3%D1%96%D0%BB%D1%8C%D0%BE%D0%B2%D0%B0%D0%BD%D0%B8%D0%B9_%D1%96%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD_%D0%B0%D0%BB%D1%8C%D1%84%D0%B0-2%D0%B0Peginterferon_alfa-2aQ420056
about
P3781
Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and RibavirinStudy of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C PatientsStudy of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis CRandomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected PatientsPegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis CRetreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose RibavirinA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of RibavirinPegasys® in Patients With Myeloproliferative DiseasesStudy of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis CA Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CA Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus InfectionPROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bPROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bSafety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusHBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon TreatedAn Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTelaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CA Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/mlThe Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis CSafety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult SubjectsAlisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CEfficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeHBsAg Related Response Guided TherapyPhase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis CAn Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis CA Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CRecombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B PatientsPharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsEvaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 448 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) InfectionLatino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
P4844
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPeginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsHepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside MaintenanceOptimization of Antiviral Therapy of Chronic HBV InfectionEffect of Teleprevir in Triple Therapy on Intrahepatic Immunological MechanismsSofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral LoadInfluence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis CEntecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis BEntecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis BPrevention of Depression in HIV/HCV Co-infected Substance Abuse PatientsLow Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected PatientsEltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver DiseaseCellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) PatientsEfficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis CPEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis CPeginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (2005-02-28)
P921
Q131742-336B5EF9-3BF6-4368-A572-5E9026571AB4Q1368780-31AB7656-C5FC-4E58-AC63-1B443671464EQ147778-E95CF0A3-C3A8-4870-BCD0-16C16E7E2F9CQ154869-5C350DB7-51DE-4F13-B243-D9A7928B58DDQ1752571-F6A8B4C1-8562-4634-9CC8-4B1EC8D3E422Q55779876-EF5F7CA5-2465-46AE-82EE-F198CE5E3946Q6853-03C44313-00E3-46D2-910C-7B1D311A022EQ948318-F64D446B-1E81-4739-8E2B-61FB3E37916C
P2176
Q61914804-0283E7CF-F56C-4B37-B2E2-CB84F6905C66Q61915185-11095D70-0D0A-4216-B4CB-FE0938D04045Q61917571-DBDE092B-D3D0-4BB7-897C-C797487A7AE7Q61917593-79C58882-6925-49D1-921E-3B7E9A98D19EQ61917984-1C5AA806-8834-4161-AD31-7D6A4FC4B2F9Q61917989-BF4EEB36-D488-423C-9E24-A7AA845A4E64Q61918300-2BC747FA-408A-488C-B1A4-A19455C442F8Q61918517-D846D1C3-1106-4675-BEA8-459438228210Q61920908-03E3F9D2-A1B6-490B-807D-152489A6FF54Q61921872-4279EFDB-9B31-436D-9D28-EBB5BA7CAB56Q61921939-6EF60F27-60D9-4BC2-8059-C9DC465DB3E8Q61932996-D3870A79-2C8F-41F2-A843-6A7B81AFF0F7Q61936623-A0A625EB-6DB8-4422-B8F5-7C8E4E2F5E99Q61938397-3FB476C6-0AEC-4BF0-8766-EFC7E0200D03Q61938535-25463CAC-836F-4A81-9CE6-6E59D0192188Q61938792-7FDB58FB-29B6-45A5-A25F-6B3C2D8CB1A4Q61939209-49E6E71D-FA92-4DA6-9A00-B750A2353063Q61939210-0D257628-5887-40C9-9F0E-35E5AA41250AQ61955555-66B89564-39F1-4B58-A0C4-61B3C165A92EQ61955556-B3954243-3F30-401E-8998-35374580FFDEQ61956171-CD72926D-E358-417A-BDAE-1B8F552E54FAQ61956173-2916CAAB-4CF1-4C6D-B7AB-8E30165B8C13Q61956175-CA8B644C-5067-4A2E-8AD8-BD1773F5532FQ61956771-66E8492B-E32A-4B9A-B6E9-B8036A9B58B4Q61956816-3AA5453B-16E4-4920-ACA3-EBDCEBB3CF67Q61957258-6A43CED2-DDC8-4188-872F-65BBE366DBA4Q61957676-18D14BEC-9E78-4604-A72C-9F609DE9BFF8Q61965746-BBB93003-90EB-43F3-9AB3-B84D148C5E4AQ61966066-D28A42CB-17C7-48D0-8038-C1858A78D044Q61967825-C7BAAE61-7D35-4BB8-8BA6-8BF3B4064445Q61967915-F392374A-8719-4CE8-8642-9B2CF4C10DD5Q61967919-F3CE8021-0E43-4A08-BA8B-788DA1B0B0B7Q61967921-803A540B-45F7-4B95-BEE2-5BA64F7E9477Q61969485-F30DE4EA-D582-4F2A-A7B0-1A0423781132Q61975325-BF44F5BB-B4CA-4998-97E4-DF411E2B02F3Q61980220-2ACF2CE6-C6C3-47BA-8E08-4226AE9518ADQ61980276-790D7ABB-F259-4E12-8E95-57DB50A6F120Q61980705-BDD2984C-CC25-4A8B-AAC8-747168A669A7Q62104868-55991C9A-CFCF-456E-A9D9-145753911F0EQ62105598-DE1B9C3C-82E3-4DE3-B800-391B9FD655CF
P4844
description
Protein
@de
Thuốc trị liệu
@vi
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Pegilirani interferon alfa-2a
@bs
Pegilirani interferon alfa-2a
@sh
Pegilirani interferon alfa-2a
@sr
Pegilirani interferon alfa-2a
@sr-el
Peginterferon alfa-2a
@en
Peginterferon alfa-2a
@id
Peginterferon alfa-2a
@pl
Peginterferon alfa-2a
@sl
Peginterferon alfa-2a
@vi
Peginterferon α
@de
type
label
Pegilirani interferon alfa-2a
@bs
Pegilirani interferon alfa-2a
@sh
Pegilirani interferon alfa-2a
@sr
Pegilirani interferon alfa-2a
@sr-el
Peginterferon alfa-2a
@en
Peginterferon alfa-2a
@id
Peginterferon alfa-2a
@pl
Peginterferon alfa-2a
@sl
Peginterferon alfa-2a
@vi
Peginterferon α
@de
altLabel
PEG-Intron alfa-2a
@sr
Pegasys
@de
Pegasys
@sl
Pegasys
@sr
Peginterferon alfa
@de
Peginterferon alfa-2a
@de
Peginterferon alfa-2a
@sr
Peginterferon alfa-2b
@de
Peginterferon alpha
@de
Peginterferon α-2a
@de
prefLabel
Pegilirani interferon alfa-2a
@bs
Pegilirani interferon alfa-2a
@sh
Pegilirani interferon alfa-2a
@sr
Pegilirani interferon alfa-2a
@sr-el
Peginterferon alfa-2a
@en
Peginterferon alfa-2a
@id
Peginterferon alfa-2a
@pl
Peginterferon alfa-2a
@sl
Peginterferon alfa-2a
@vi
Peginterferon α
@de
P2175
P31
P486
P592
P6366
P646
P665
P2115
N0000148781
N0000178330
P2175
P2275
Peginterferon alfa-2a
@en
P231
198153-51-4
P267
P3345
P373
Interferon-alpha 2a
P3780
P486
P592
CHEMBL1201560
P6366
2776235749
2908519312
P646
P652
Q46947FE7K